HEIDE BAJNRAUH — Lobbyist Profile | Poliscope

HEIDE BAJNRAUH

Reported covered position: Senator McCain Intern 94-96;LSA96-97

Filings

133

Clients

Firms

Years active

2024–2026

Associated filing income

$3,327,500

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
CARLSMED, INC.	15	2024–2026
MILLENNIUM HEALTH	14	2024–2026
INARI MEDICAL	10	2024–2026
MAINSTAY MEDICAL	9	2024
SENSEONICS, INC.	9	2024–2026
ALEXION PHARMACEUTICALS	8	2024–2025

Lobbying firms

Firm	Filings	Years
MANATT, PHELPS, AND PHILLIPS	133	2024–2026

Bills explicitly cited in this lobbyist’s assigned issues (4)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 5269

RESULTS Act

Client: MILLENNIUM HEALTH · Firm: MANATT, PHELPS, AND PHILLIPS

Open original LDA filing ↗

Cited source text

Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)

H.R. 5269

RESULTS Act

Client: MILLENNIUM HEALTH · Firm: MANATT, PHELPS, AND PHILLIPS

Open original LDA filing ↗

Cited source text

Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)

Original LDA source filings (100)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to device reimbursement

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Source: Senate LDA

Show 96 more original filings

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2026 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

DATASPRING via MANATT, PHELPS, AND PHILLIPS

2026 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Provider directory and provider credentialing issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2026 · second_quarter · Q2

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

DATASPRING via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · Q1

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Provider directory and provider credentialing issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

STRYKER CORPORATION (FKA INARI MEDICAL) via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Funding for blood clot education and awareness

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · Q1

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

HCR

Health Issues

Issues related to Medical Device Reimbursement

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

DATASPRING via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

National Provider Directory and provider credentialing issues

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2026 · first_quarter · Q1

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2025 · fourth_quarter · Q4

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · fourth_quarter · Q4

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare payment issue for physicians and hospital outpatient departments, Centers for Medicare & Medicaid Services.

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement, SAMHSA and HHS.

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement, SAMHSA and HHS.

STRYKER CORPORATION (FKA INARI MEDICAL) via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations

MMM

Medicare/Medicaid

Appropriations

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

NEW YORK STEM CELL FOUNDATION via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Appropriations and Healthcare

HCR

Health Issues

Appropriations and Healthcare

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $35,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · third_quarter · Q3

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare payment issue for physicians and hospital outpatient departments

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement.

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement.

STRYKER CORPORATION (FKA INARI MEDICAL) via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations

MMM

Medicare/Medicaid

Appropriations

GUARDANT HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · 2T

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations and Healthcare

BUD

Budget/Appropriations

Appropriations and Healthcare

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

NEW YORK STEM CELL FOUNDATION via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Appropriations and Healthcare

HCR

Health Issues

Appropriations and Healthcare

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

HEALTH ACCESS CA via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · 2@

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Impact of Medicaid cuts being considered under reconciliation.

HEALTH ACCESS CA via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · 2T

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Impact of Medicaid cuts being considered under reconciliation.

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · second_quarter · Q2

Firm income: $67,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

NEW YORK STEM CELL FOUNDATION via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Appropriations and Healthcare

HCR

Health Issues

Appropriations and Healthcare

GUARDANT HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations and Healthcare

BUD

Budget/Appropriations

Appropriations and Healthcare

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare payment issue for physicians and hospital outpatient departments

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to drugs of abuse testing reimbursement.

MMM

Medicare/Medicaid

Issues related to drugs of abuse testing reimbursement.

STRYKER CORPORATION (FKA INARI MEDICAL) via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations

MMM

Medicare/Medicaid

Appropriations

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · 1A

Firm income: $67,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $67,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

HEALTH ACCESS CA via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · Q1

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Impact of Medicaid cuts being considered under reconciliation.

HEALTH ACCESS CA via MANATT, PHELPS, AND PHILLIPS

2025 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Impact of Medicaid cuts being considered under reconciliation.

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4A

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests

ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of in vitro diagnostics and lab-developed tests.

NEW YORK STEM CELL FOUNDATION via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Appropriations and Healthcare.

HCR

Health Issues

Appropriations and Healthcare.

GUARDANT HEALTH via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations and Healthcare.

BUD

Budget/Appropriations

Appropriations and Healthcare.

CARLSMED INC via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to medical device reimbursement.

HCR

Health Issues

Issues related to medical device reimbursement.

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare payment issue for physicians and hospital outpatient departments.

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Drugs of Abuse Testing Reimbursement.

MMM

Medicare/Medicaid

Issues related to Drugs of Abuse Testing Reimbursement.

MAINSTAY MEDICAL via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · 4T

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to medical device reimbursement.

HCR

Health Issues

Issues related to medical device reimbursement

INARI MEDICAL via MANATT, PHELPS, AND PHILLIPS

2024 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Appropriations

HCR

Health Issues

Appropriations

MILLENNIUM HEALTH via MANATT, PHELPS, AND PHILLIPS

2024 · third_quarter · 3A

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Drugs of Abuse Testing Reimbursement.

HCR

Health Issues

Issues related to Drugs of Abuse Testing Reimbursement.

MAINSTAY MEDICAL via MANATT, PHELPS, AND PHILLIPS

2024 · third_quarter · 3A

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to medical device reimbursement

MMM

Medicare/Medicaid

Issues related to medical device reimbursement.

INARI MEDICAL via MANATT, PHELPS, AND PHILLIPS

2024 · third_quarter · 3A

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Appropriations

MMM

Medicare/Medicaid

Appropriations

SENSEONICS, INC. via MANATT, PHELPS, AND PHILLIPS

2024 · third_quarter · 3A

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare payment issue for physicians and hospital outpatient departments.